Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01033825 · ClinicalTrials.gov registry record · Phase 3
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 310
- Enrollment target
NCT01033825 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 310 participants.
The verdict
NCT01033825, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 310 participants
- Enrollment target
Study Summary
To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
Interventions
- DRUG Ciclesonide HFA Nasal Aerosol 320 mcg
- DRUG Ciclesonide HFA Nasal Aerosol 160 mcg
- DRUG HFA Nasal Aerosol placebo
- DRUG Ciclesonide Aqueous Nasal Spray 200 mcg
- DRUG AQ Nasal Spray Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01033825
The ClinicalTrials.gov registry entry for NCT01033825 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ciclesonide HFA Nasal Aerosol 320 mcg is the first listed.
NCT01033825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01033825 about?
NCT01033825 is a clinical study titled "Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis". To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
What is the current status of trial NCT01033825?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 310 participants. The study started on 2010-01. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01033825?
The interventions under investigation include: Ciclesonide HFA Nasal Aerosol 320 mcg (DRUG), Ciclesonide HFA Nasal Aerosol 160 mcg (DRUG), HFA Nasal Aerosol placebo (DRUG), Ciclesonide Aqueous Nasal Spray 200 mcg (DRUG), AQ Nasal Spray Placebo (DRUG).
Who is sponsoring clinical trial NCT01033825?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.